

Friday Satellite Symposia

Preceding the 63rd ASH Annual Meeting and Exposition

Amplifying the Role of Accurate
Diagnosis and New Therapeutic
Options in the Treatment of

Hemolytic Anemias

VIRTUAL SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

11:00 AM - 1:30 PM CST

PROGRAM CHAIR

Carlos M. De Castro III, MD

For more information, visit us at...

gotoper.com



Stay connected! Follow us @GoToPER and share your thoughts and photos by using #gotoPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias**.

Rare hemolytic anemias, including atypical hemolytic uremic syndrome (aHUS), pyruvate kinase deficiency (PKD), warm autoimmune hemolytic anemia (wAIHA), paroxysmal nocturnal hemoglobinuria (PNH), and aplastic anemia (AA), pose significant challenges to the hematology/oncology community. As the diagnostic workup is complex and multifaceted, accurate diagnoses are essential to improving patient outcomes. The educational gaps regarding awareness of these rare disorders, their diagnostic criteria, methods for differential diagnosis, and current/emerging treatment options have been further deepened by the COVID-19 pandemic. Therefore, the present format will give clinicians the opportunity to review the latest guidelines on diagnoses for hemolytic anemias, to reflect on potential real-world clinical scenarios through case-based discussion, and to hear expert insight on how they might integrate relevant evidence and emerging approaches into treatment paradigms for these hemolytic anemias.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with hemolytic anemias.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Carlos M. De Castro III, MD

Professor of Medicine
Duke University Medical Center
Durham, NC

Jim Palatine, RPh, MBA

President
Physicians' Education Resource®, LLC
Cranbury, NJ
jpalatine@mjhlifesciences.com

AGENDA

10:15 AM	Registration & Brunch	
11:00 AM	Welcome and Introductions	Carlos M. De Castro III, MD
11:05 AM	Hemolytic Anemia 101: Overview of Diseases, Diagnoses, and Epidemiology	Carlos M. De Castro III, MD
11:20 AM	Paroxysmal Nocturnal Hemoglobinuria (PNH) & Case 1	Phillip Scheinberg, MD
11:45 AM	Atypical Hemolytic Uremic Syndrome (aHUS) & Case 2	Ara Metjian, MD
12:10 PM	Pyruvate Kinase Deficiency (PKD) & Case 3	Jennifer A. Rothman, MD
12:30 PM	Warm Autoimmune Hemolytic Anemia (wAIHA) & Case 4	Caroline I. Piatek, MD
12:55 PM	Aplastic Anemia (AA) & Case 5	Carlos M. De Castro III, MD
1:15 PM	Question & Answer Session	All Faculty
1:30 PM	Closing Remarks & Adjourn	Carlos M. De Castro III, MD

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

<i>The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™</i>	Honolulu, HI	January 21
<i>20th Annual Winter Lung Conference®</i>	Hollywood, FL	February 3-5
<i>19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®</i>	Dallas, TX	February 4
<i>27th Annual International Congress on Hematologic Malignancies®</i>	Miami Beach, FL	February 23-26
<i>40th Annual Miami Breast Cancer Conference®</i>	Miami Beach, FL	March 2-5
<i>NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies</i>	New York, NY	March 10-11
<i>8th Annual School of Gastrointestinal Oncology®</i>	Orlando, FL	May 6
<i>7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards</i>		May 6
<i>14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies</i>		May 13
<i>22nd Annual International Congress on the Future of Breast Cancer® East</i>	New York, NY	July 15-16
<i>24th Annual International Lung Cancer Congress®</i>	Huntington Beach, CA	July 27-29
<i>22nd Annual International Congress on the Future of Breast Cancer® West</i>	San Diego, CA	July 28-29
<i>20th Annual Meeting of the International Society of Gastrointestinal Oncology®</i>	Tempe, AZ	October 13-14
<i>21st Annual School of Breast Oncology®</i>	Atlanta, GA	November 2-4
<i>41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®</i>	New York, NY	November 8-10
<i>18th Annual New York Lung Cancers Symposium®</i>	New York, NY	November 11



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

Target Audience

This educational activity is directed toward medical oncologists, hematologic oncologists, hematologists, hematopathologists, and other health care professionals involved in the treatment of hemolytic anemias.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Determine the pathophysiological mechanisms of the rare hemolytic anemias PNH, aHUS, PKD, wAIHA, and aplastic anemia (AA)
- Explain recent diagnostic criteria for PNH, aHUS, PKD, wAIHA, and AA, with a focus on differential diagnosis methods
- Evaluate efficacy/safety data on current and emerging therapeutic options for PNH, aHUS, PKD, wAIHA, and AA
- Apply evidence from pivotal trials that assessed therapeutic options for hemolytic anemias to manage real-world clinical scenarios of patients with these diseases, including treatment-related toxicity management

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EST on Monday, December 12, 2022. To access these materials, please visit <https://www.gotoper.com/anemia1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/anemia1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc, Apellis Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, and Rigel Pharmaceuticals, Inc.

Thank you for attending **Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias!**

To register for upcoming accredited CE live activity or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose:
Ara Metjian, MD, and the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
Carlos M. De Castro III, MD		Novartis, Biocryst	Apellis Pharmaceuticals, Alexion Pharmaceuticals	DSMB - Regeneron
Caroline Piatek, MD		Rigel Pharmaceuticals		
Jennifer Rothman, MD	Agios Pharmaceuticals, Novartis, Pfizer, Sobi, Dova, Sanofi	Agios Pharmaceuticals, Sobi, Novartis		
Phillip Scheinberg, MD	Pfizer, Alnylam	Novartis, AbbVie, Roche, Alexion, Pfizer, Biocryst, AstraZeneca	Novartis, Pfizer, Alexion, AstraZeneca, Amgen, Bristol Myers Squibb	

**Information accurate at time of printing*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer


This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Carlos M. De Castro III, MD

Professor of Medicine
Duke University Medical Center
Durham, NC

Carlos M. De Castro, MD, is currently a professor in medicine at Duke University. He graduated from Duke University in 1985 with a B.S.E. in Biomedical Engineering. He then attended medical school at the University of Texas Southwestern Medical School in Dallas, followed by a residency at Parkland Memorial Hospital in Dallas. He returned to Duke in 1988 for a fellowship in Hematology-Oncology, and then joined the faculty at Duke in 1991. He has served as the medical director of the Apheresis Unit, the Outpatient Treatment Center, and the 9100 Malignant Hematology ward. He is currently the Program Director for the Hematology-Oncology Fellowship Program. He has won numerous teaching awards including the Wendell F. Rosse Teaching Award and the Duke University Master Clinician Award. His clinical research has focused on hematopoiesis and conditions of bone marrow failure including myelodysplastic syndromes, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Faculty



Ara Metjian, MD

Associate Professor
University of Colorado Anschutz School of Medicine
Aurora, CO



Caroline Piatek, MD

Associate Professor of Clinical Medicine
Jane Anne Nohl Division of Hematology
and Center for the Study of Blood Diseases
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Caroline Piatek, MD, is an associate professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine of USC. She is currently the fellowship director for the USC/LAC+USC Medical Hematology Fellowship Program. Dr. Piatek's clinical focus is in non-malignant hematology. Her research interests include immune thrombocytopenia, warm autoimmune hemolytic anemia, cancer-associated thrombosis and paroxysmal nocturnal hemoglobinuria.

After earning her medical degree from Creighton University School of Medicine, Dr. Piatek completed internal medicine residency and hematology/medical oncology fellowship at the University of Southern California.

Faculty

**Jennifer Rothman, MD**

Associate Professor
Clinical Director, Pediatric Hematology/Oncology
Program Director, Pediatric Hematology/Oncology Fellowship Program
Division of Pediatric Hematology and Oncology
Duke University Medical Center
Durham, NC

Jennifer Rothman, MD, is a pediatric hematologist/oncologist at Duke University Medical Center. She currently serves as the Medical Director of Pediatric Hematology/Oncology and the Director of the Duke Pediatric Sickle Cell Program. She has a clinical and research interest in congenital anemias. She completed her pediatric training and pediatric hematology/oncology training at the Children's Hospital of Philadelphia.

**Phillip Scheinberg, MD**

Chief of Clinical Hematology
Hospital A Beneficência Portuguesa
Sao Paulo, Brazil

Phillip Scheinberg, MD, graduated in medicine from the University of Santo Amaro, Sao Paulo, Brazil in 1995. He then undertook residencies in Internal Medicine at the University of Sao Paulo (1996–1997) and at Mount Sinai Medical Center, Florida, USA (1997–2000). From 2000 to 2001, he worked as medical chief resident at Mount Sinai Medical Center.


Dr. Scheinberg undertook his hematology-oncology fellowship and training at the Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health from 2001 to 2006. He then remained on staff at the Hematology Branch of the NHLBI from 2006 to 2011, where he developed several clinical protocols in bone marrow failure syndromes as well as conducted laboratory research in bone marrow failure syndromes, bone marrow transplantation, cellular immunity against viral, tumoral and allogeneic antigens. He is currently head of the division of hematology, Hospital A Beneficência Portuguesa, Sao Paulo, Brazil.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from*→ **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.



**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ash22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com